Related Experiment Video
Updated: Jun 15, 2025
07:12
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
Published on: August 2, 2021
3.5K
Rationale for Adjunctive Treatment Targeting Multiple Mechanisms in Schizophrenia
Bruce J Kinon1,2, Stefan Leucht3, Carol Tamminga4
1Karuna Therapeutics, Boston, Massachusetts.
The Journal of Clinical Psychiatry
|August 28, 2024
Summary
New antipsychotic treatments targeting non-dopamine pathways are needed for schizophrenia. Novel agents may improve outcomes for patients with treatment resistance or side effects from current dopamine D2 receptor blockers.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Schizophrenia treatment remains challenging, with current dopamine D2 receptor antagonists having limitations.
- Existing antipsychotics are often ineffective for negative symptoms and cognitive deficits, and cause side effects.
- Schizophrenia pathophysiology involves multiple neurotransmitter systems beyond dopamine.
Purpose of the Study:
- To highlight the unmet need for comprehensive schizophrenia symptom management.
- To explore novel therapeutic strategies beyond dopamine D2 receptor antagonism.
Main Methods:
- Review of current schizophrenia treatment limitations.
- Analysis of emerging evidence on non-dopaminergic pathways in schizophrenia.
Main Results:
- Current antipsychotics primarily target positive symptoms and have significant side effects.
- Negative symptoms and cognitive impairments in schizophrenia are inadequately addressed.
- Dysfunction in glutamate, acetylcholine, serotonin, and GABA systems is implicated.
Conclusions:
- There is a critical need for treatments addressing all core schizophrenia symptoms.
- Nondopaminergic antipsychotics show promise as adjunctive therapies.
- Novel agents could benefit patients with treatment resistance or poor tolerance to current medications.
Related Concept Videos
01:28Drug Therapy
40
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
40
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
01:26Psychosis: Goals of Pharmacotherapy
113
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
113
01:23Antidepressant Drugs: MAOIs and Other Agents
205
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
205
01:28Psychosis and Antipsychotic Drugs: Overview
203
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
203
01:24Parkinson's Disease: Treatment
239
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
239